¾È±¹¾Æ½ÃŬ·Î¹öÅ©¸² 10g  Ahngook Acyclovir Cream  
                    
                 
               
              
                
                     ÀϹÝÀǾàǰ | ±Þ¿©   
                        
                    	
                    
                 
               
              
                
					  
                  
				  
                 
               
              
              
              
              
                 
              
                
                    
                       
                      ¾Ë¸²:  
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. 
                     
                  
 
               
            
              
                
                   
                   
                   
                   
		   
                 
               
              
                
                  
                     
                    
                       Àü¹®/ÀÏ¹Ý 
		              
                    ÀϹÝ
                       
                      
                        
                        
                          
                            
                                
                             
                           
                           
                           
                          
                          ÀüÁúÀÌ °í¸¥ Èò»öÀÇ Å©¸²Á¦  
                          
                           
                          
			              
                            
                            
							  
							 
                             
                           
                          
                          
                            
                              
                               
                             
                           
                          
                          
                            
                            
							 
                             
                           
                          
                        
                        
                       
                     
                    
                      
					   Á¦Á¶È¸»ç 
                      
                       
                        ¾È±¹¾àǰ(ÁÖ) 
                      
                       
                     
                    
                      
					   ÆÇ¸Åȸ»ç 
                      
                       
			            ¾È±¹¾àǰ(ÁÖ) 
                      
                       
                     
                      
                      
                      
					   Çã°¡Á¤º¸ 
                      
                      
                                          Á¤»ó                   
                                          
                          
                                (2005.09.12) 
                           
                            
                       
                     
                    
                     
                        
	    				   BIT ¾àÈ¿ºÐ·ù 
                        
                          ¿Ü¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ (Antivirals : Skin & Mucous Membrane)
                         
                     
                    
                    
                      
					   º¹ÁöºÎºÐ·ù 
                      269[±âŸÀÇ ¿ÜÇÇ¿ë¾à                                                 ] 
                     
                    
                      
					   û±¸ÄÚµå(KDÄÚµå)    ºñ±Þ¿©Á¡°ËÄÚµå 
                      
                      
                      
                        
650201332\12,872 ¿ø/10g/°³(2020.07.01) (ÇöÀç¾à°¡) 
                         
                        
						     
						     
                         
                      
                     
                       
                     
                     
                    
                       ATCÄÚµå 
                      Aciclovir  / D06BB03 
                     
                    
                    
                       NDCÄÚµå 
                      
                        [Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]  
                        [Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]  
                        [NDC Number Search _ NDCÄÚµå·Î °Ë»ö]  
                       
                                         
                    
                      
					   ¼ººÐ / ÇÔ·®  
                      
			
			
			[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]   
			
			 
					                            
                       
                     
                        
                      
                      
					   ÷°¡Á¦ 
                      
                      
                           ¼¼Åº¿Ã ,
                          
                           ¼Ò¸£ºñź½ºÅ׾Ʒ¹ÀÌÆ® ,
                          
                           ½ºÅ׾Ƹ£»ê ,
                          
                           ½ÃÆ®¸£»ê¼öȹ° ,
                          
                           À¯µ¿ÆÄ¶óÇÉ ,
                          
                           Á¤Á¦¼ö ,
                          
                           ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿ ,
                          
                           ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ ,
                          
                           Æú¸®¼Ò¸£º£ÀÌÆ®60 ,
                          
                          ÇÁ·ÎÇÊ·»±Û¸®ÄÝ 
                                          
                       
                     
                  
                  
                 
               
            
 
            
         
      
       
   
   
  
    
      
     
     
                   
                                        
                                             
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
  
    
      
     
 
 
    
   
    
      
        À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
        ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
        ·Î±×ÀÎ  ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
      
     
   
  
     
   
  
  
    
      
  
    
       
      
        
          
            
              Çã°¡Á¤º¸ 
             
          
         
       
       
      
  
    Ç׸ñ 
    ³»¿ë 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× 
    
      
      
        
        650201332  
	    
	    
            [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]   
          
        
        
        
              \12,872 ¿ø/10g/°³(2020.07.01) (ÇöÀç¾à°¡) 
              
	 
	   
	   
       
      
       
       
     
      
      
     
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]  
      
      [Áúº´ÄÚµåÁ¶È¸]  
     
     
   
   
    ºü¸¥Á¶È¸ 
    
      
       
   
  
  
  
   
    Á¦Ç°¼º»ó 
    ÀüÁúÀÌ °í¸¥ Èò»öÀÇ Å©¸²Á¦  [Á¦ÇüÁ¤º¸ È®ÀÎ]    
   
  
  
  
  
  
   
    Æ÷À塤À¯Åë´ÜÀ§ 
    10g 
   
  
  
  
   
    Æ÷À塤ÄÚµå´ÜÀ§ 
    
        
        
            ¾àǰ±Ô°Ý  
            ´ÜÀ§  
            Æ÷ÀåÇüÅ  
            ´ëÇ¥ÄÚµå  
            Ç¥ÁØÄÚµå  
            ºñ°í  
	     
        
        
            10±×·¥ 
            1 °³ 
            Æ©ºê 
            8806502013300 
            8806502013324 
             
	     
        
        
     
   
      
  
  	
   
    ÁÖ¼ººÐÄÚµå 
    
      102937CCM  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]  
     
   
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    Çã°¡»çÇ× ¿ø¹®Á¶È¸ 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸]   
     
   
  
  
  
  
     
  
  
  
   
    È¿´ÉÈ¿°ú 
     
    [ÀûÀÀÁõ º° °Ë»ö]   
      
    
     
	 
      ´Ü¼øÆ÷Áø(¹°Áý) ¹ÙÀÌ·¯½º °¨¿°Áõ(ÃÊ±â ¹× Àç¹ß¼º »ý½Ä±â Æ÷Áø(¹°Áý)°ú ±¸¼øÆ÷Áø(ÀÔ¼ú¹°Áý) Æ÷ÇÔ)
      
     
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    ¿ë¹ý¿ë·® 
     
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.  
    
     
      
      
      [󹿾à¾î]  
       1) ÀÌ ¾àÀº ¾à 4½Ã°£ °£°ÝÀ¸·Î 1ÀÏ 5ȸ ȯºÎ¿¡ ¹Ù¸¥´Ù. 
 2) Ä¡·á´Â 5Àϰ£ °è¼ÓÇÏ¿©¾ß Çϸç, 5Àϰ£ »ç¿ë ÈÄ¿¡µµ Ä¡·áµÇÁö ¾ÊÀ» °æ¿ì¿¡´Â 5Àϰ£ ´õ »ç¿ëÇÒ ¼ö ÀÖ´Ù.     
      	
     
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    ±Ý±â 
      1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àְųª ÈÇÐÀû ºÒ³»¼º ȯÀÚ 
 2) ¼öÀ¯ºÎ 
 3) ¼Ò¾Æ 
   
  
  
  
  
   
    ½ÅÁßÅõ¿© 
      1) ¿¡ÀÌÁî ȯÀÚ ¶Ç´Â °ñ¼ö(»À¼ÓÁú)ÀÌ½Ä È¯ÀÚ µî ¸é¿ª°áÇÌ È¯ÀÚ 
 2) ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.(ÇÔÀ¯Á¦Ç°¿¡ ÇÑÇÔ)
 
   
  
    
  
  
  
  
  
   
    ÀÌ»ó¹ÝÀÀ 
     
       1) ±Ë¾çÀÌ »ý±ä »ý½Ä±â ºÎÀ§ÀÇ Æ¯¼º»ó ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ¾ÐÅë µîÀÇ ºÒÄè°¨À» ´À³¥ ¼ö ÀÖ´Ù. 
 2) ÀϽÃÀûÀÎ ÀÛ¿°¨, ÀÚÅëÀ» Æ÷ÇÔÇÏ´Â °¡º¿î µ¿Åë ¹× Á¢ÃËÇǺο°, È«¹Ý¼º ¹ßÁø, ½ÀÁø, ¾Ë·¹¸£±â¹ÝÀÀ ¹× ¶§¶§·Î µµÆ÷ºÎÀ§ÀÇ Àڱذ¨, °¡·Á¿ò, ¿ÜÀ½¿°, ¾È¸é ºÎÁ¾, ÇǺΠŻ»ö, µÎµå·¯  ±â, ¹ßÁø, ¼Ò¼öÆ÷¼º ¹ßÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
 3) È«¹Ý, °¡·Á¿òÀÌ ³ªÅ¸³ª°Å³ª ÇǺΰ¡ ¾à°£ °ÇÁ¶ÇØÁö°í ¹þ°ÜÁú ¼ö ÀÖ´Ù.
      
     
   
        
  
  
    
   
    »óÈ£ÀÛ¿ë 
      ÀÌ ¾à°ú ¿¬°ü¼ºÀº ¹àÇôÁöÁö ¾Ê¾ÒÀ¸³ª, Àü½ÅÅõ¿©ÇÑ ¾Æ½ÃŬ·Î¹öÀÇ Ç÷Àå ¹Ý°¨±â ¹× AUC°¡ ÇÁ·Îº£³×½Ãµå¿¡ ÀÇÇØ Áõ°¡ÇÏ¿´´Ù. 
   
  
    
  
  
       	
  
  
   
    Off-label Usage 
    
      
	[Á¶È¸]      
     
   
     
  
  
  
  
  
   
    Related FDA Approved Drug 
    
       
     
      
  
  
 
    
   
  
    
       
      
        
          
            
              Á¤º¸¿ä¾à         
             
          
         
             	    
       
      
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸ 
    
  
  
    
  
    
    
   
  
    
       
      
        
          
            
              ÄÚµå ¹× ºÐ·ùÁ¤º¸         
             
          
         
             	    
       
      	  
    
   
  
    
       
      
        
          
            
              Á¦Ç°Á¤º¸            
             
          
         
             	  
       
      
  
    Ç׸ñ 
    ³»¿ë 
   
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× 
    
      
      
        
        650201332  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]   
          
        
        
        
           \12,872 ¿ø/10g/°³(2020.07.01) (Ãֽžడ) 
              
	 
	   
	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]  
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]  
    
     
   
  
  
   
    Á¦Ç°¼º»ó 
    
      ÀüÁúÀÌ °í¸¥ Èò»öÀÇ Å©¸²Á¦  
      
	  [Á¦ÇüÁ¤º¸ È®ÀÎ]  
       
   
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    Æ÷À塤À¯Åë´ÜÀ§ 
    10g 
   
  
  
  
   
    º¸°ü¹æ¹ý 
    ±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü 
   
  
  
                                                          															
  
  
  
  
  
       
  
  
  
  
   
    Brandname Á¤º¸ 
    
      Acyclovir Brand Names/Synonyms  
AC2 
 Aciclovier 
 Aciclovir 
 Acycloguanosine 
 Acyclovir Sodium 
 Alti-Acyclovir 
 Avirax 
 Valtrex 
 Vipral 
 Virorax 
 Wellcome-248u 
 Zovirax 
 Zovirax Wellstat Pac 
 Zovirax Zostab Pac   Brand Name Mixtures  Zovirax Injection (Zovirax sodium)Chemical IUPAC Name  2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one
     
   
   
 
    
   
  
    
       
      
        
          
            
              º¹¾àÁ¤º¸            
             
          
         
             	  
       
      
  
    Ç׸ñ 
    ³»¿ë 
   
   
    LACTmed ¹Ù·Î°¡±â 
    
      
        [¹Ù·Î°¡±â]  
     
     
  
  
  
  
   
    Ãà¾àº¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
       
  
  
   
    º¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
                                                          															
  
   
  
  
   
    ÀӺο¡´ëÇÑÅõ¿© 
    
      
      
        
	      
	      
	        *   
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	          
	         
	      
	       
	   
	  
	      
	   
	  
	    
	     FDA : Bµî±Þ 
				        	
					  
					
	   
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   
	 
	
	  
	      
	      
	        *   
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. 
	         
	         
	      
	        *   
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í  ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù. 
	         
	         
	      
	   
	 
      
     
   
  
  
  	   
  
  	   
  
  	   
  
  
  
  
  
  
  
  	
  
  
  	
  
  
   
    Á¦Çüº° º¹¾àÁöµµ 
    [Å©¸²]  
   
  
  
   
    º¸°ü»ó ÁÖÀÇ 
    
      
    	
     
   
  
  
   
    Á¶Á¦½Ã ÁÖÀÇ 
    
      
    	
     
      
 
    
   
  
    
       
      
        
          
            
              ½É»çÁ¤º¸            
             
          
         
             	  
       
       
    
     
  
    
       
      
        
          
            
              ÇмúÁ¤º¸          
             
          
         
             	  
       
       
    
     
  
    
       
      
        
          
            
              »ç¿ëÀÚÄÁÅÙÃ÷           
             
          
         
             	  
       
       
    
         
 
     
   
   
     
   
  
    
      
        
          
            
              
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-29
               
              
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                 
                   
             
                         
      
           
          
                
                    
                       ¾Ë¸² 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  
                    
                  
 
               
      
      
                
                    
                       °æ°í 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù. 
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 
  
                  
 
               
  
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
  
  The database contains the following fields:
The generic name of each chemical
For module A10 (liver enzyme composite module):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method)
Number of endpoints at which each compound is marginally active (M)
Number of endpoints at which each compound is active (A)
For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method)
Number of ADR reports for each compound, given as <4 or ¡Ã4
Reporting Index value for each compound, except where no shipping units were available (NSU)
Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period.
ACYCLOVIR [GGT Increase] [Composite Activity] (Score)   I  (Marginal)   0 (Active)   0 [Alkaline Phosphatase Increase] (Activity Score)   I  (Number of Rpts)   ¡Ã4 (Index value)   0.9 [SGOT Increase] (Activity Score)   I  (Number of Rpts)   ¡Ã4 (Index value)   0.9 [SGPT Increase] (Activity Score)   I  (Number of Rpts)   <4 (Index value)   0.1 [LDH Increase] (Activity Score)   I  (Number of Rpts)   <4 (Index value)   0.1 [GGT Increase] (Activity Score)   I  (Number of Rpts)   <4 (Index value)   0 
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ